<DOC>
	<DOCNO>NCT01900899</DOCNO>
	<brief_summary>The purpose study evaluate long-term antibody persistence well safety GSK Biologicals ' MenACWY-TT vaccine versus Meningitec 6 year booster vaccination administer healthy 5 year old child study MENACWY-TT-048 EXT : 039 Y2 , 3 , 4 , 5 ( NCT00955682 ) , prim vaccine study MENACWY-TT-039 ( NCT00474266 ) 12 23 month age .</brief_summary>
	<brief_title>Study Evaluate Persistence Antibodies After GlaxoSmithKline ( GSK ) Biologicals ' Meningococcal Vaccine ( GSK134612 ) Healthy Children</brief_title>
	<detailed_description>The subject study allocate group study MENACWY-TT-048 EXT : 039 Y2 , 3 , 4 , 5 ( NCT00955682 ) . No vaccine administer long-term persistence study .</detailed_description>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>All subject must satisfy ALL follow criterion study entry : Subjects ' parent ( ) /Legally Acceptable Representative ( ) [ LAR ( ) ] , opinion investigator , comply requirement protocol . A male female receive primary booster vaccination MenACWYTT Meningitec vaccine study MENACWYTT039 ( 109670 ) MENACWYTT048 EXT : 039 Y2 , 3 , 4 , 5 ( 112036 ) , respectively . Written inform consent obtain parent ( ) /LAR ( ) subject . Healthy subject establish medical history clinical examination enter study . The following criterion check time study entry . If ANY exclusion criterion applies , subject must include study : Child care . History meningococcal disease . Administration meningococcal polysaccharide meningococcal polysaccharide conjugate vaccine outside study MENACWYTT039 ( 109670 ) MENACWYTT048 EXT : 039 Y2 , 3 , 4 , 5 ( 112036 ) . Any confirm suspect immunosuppressive immunodeficient condition , base medical history physical examination . Bleeding disorder , thrombocytopenia , subject anticoagulant therapy .</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Children</keyword>
	<keyword>Neisseria meningitidis</keyword>
	<keyword>Long-term antibody persistence</keyword>
	<keyword>Safety</keyword>
	<keyword>Serogroups A , C , W-135 , Y</keyword>
</DOC>